MMS Holdings, Inc   Report issue

For profit Phase 1
Founded: Chicago IL United States (2006)

Organization Overview

First Clinical Trial
2017
NCT03272165
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

MMS Holdings, Inc

Active Ingredients

Drugs in Phase 1 Trials (1)

medi1341 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1